Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hu2E2-GAALIE
- Development stage
- Preclinical
- Lead developer
- Fujian Medical University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
hu2E2-GAALIE is a humanized, T-cell receptor (TCR)-like monoclonal antibody designed for the treatment of NPM1-mutated acute myeloid leukemia (AML). It specifically targets the neoantigen complex formed by the NPM1mutA283-291 peptide and the HLA-A*02:01 molecule, allowing it to recognize intracellular mutations that are typically inaccessible to standard antibodies. The antibody is engineered with the GAALIE Fc-modification (G236A/A330L/I332E), which significantly increases its affinity for the FcγRIIIa (CD16a) receptor, thereby enhancing its ability to mediate antibody-dependent cellular cytotoxicity (ADCC). Developed by researchers at Fujian Medical University and Xiamen University, hu2E2-GAALIE has demonstrated potent anti-tumor activity in both in vitro assays and in vivo humanized mouse models of AML.
- Other names
- humanized 2E2-GAALIEhumanized2E2-GAALIEhumanized-2E2-GAALIE
02
Targets
FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)NPM1mut-A283-291/HLA-A*02:01 (Nucleophosmin 1 mutant A283-291 peptide presented by Human Leukocyte Antigen A*02:01)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)FCGRT (Neonatal crystallizable fragment receptor)
Beyond the preview
Go deeper on hu2E2-GAALIE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hu2E2-GAALIE.